⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of UroGen Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
UroGen Pharma
↗Princeton, New Jersey, USA
UroGen Pharma is a commercial-stage biotechnology company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. The company leverages its proprietary RTGel® reverse-thermal hydrogel technology, which enables sustained-release drug delivery to improve the therapeutic profiles of existing medications by allowing longer exposure of urinary tract tissue to treatment.
Headquartered in Princeton, New Jersey, with significant operations in Israel, UroGen focuses on non-surgical treatment pathways for urological cancers. Its portfolio includes FDA-approved products such as JELMYTO® and ZUSDURI™, aimed at providing patients with alternatives to repetitive surgical procedures like transurethral resection of bladder tumor (TURBT).
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2004
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
STOCK
Exchange:NASDAQ
Ticker:URGN
Market Cap:$1.6B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial / Phase 3
Modalities:Small molecule, Hydrogel-based sustained release
Active Trials:0
Trial Phases:Phase 3: 1
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Agenus Inc. (licensing for urinary tract cancer treatments), MD Anderson (research collaboration on UGN-201 and UGN-301), medac GmbH (licensing and supply for UGN-103 and UGN-104)
COMPETITION
Position:Niche Player
Competitors:Teva Pharmaceuticals
LEADERSHIP
Key Executives:
Elizabeth Barrett - President and CEO
Chris Degnan - CFO
Board Members:Arie Belldegrun
LINKS
Website:urogen.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with UroGen Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.